Frankfurt - Delayed Quote EUR

Pharmanutra S.p.A. (761.F)

49.60
-0.05
(-0.10%)
At close: 9:43:36 AM GMT+2
Loading Chart for 761.F
  • Previous Close 49.65
  • Open 49.20
  • Bid 50.00 x --
  • Ask 51.60 x --
  • Day's Range 49.20 - 49.60
  • 52 Week Range 45.00 - 60.30
  • Volume 6
  • Avg. Volume 0
  • Market Cap (intraday) 482.891M
  • Beta (5Y Monthly) 0.30
  • PE Ratio (TTM) 29.01
  • EPS (TTM) 1.71
  • Earnings Date May 12, 2025
  • Forward Dividend & Yield 1.00 (2.01%)
  • Ex-Dividend Date May 5, 2025
  • 1y Target Est --

Pharmanutra S.p.A., a pharmaceutical and nutraceutical company, researches, designs, develops, and markets nutritional supplements and medical devices in Italy, Europe, the Middle East, South America, Far East, and internationally. The company produces and distributes raw materials and active ingredients for the food, pharmaceutical, and dietary supplement industries. It also offers iron deficiency, inflammation, mineral and vitamin, muscle and joint, sports nutrition, ophthalmic, and night rest products; and medical instrumentation and software for body bioimpedance analysis. The company sells its products through sales representatives, wholesalers, pharmacies, para-pharmacies, agents, distributors, online sales, local partners, and tenders. Pharmanutra S.p.A. was founded in 2003 and is based in Pisa, Italy.

www.pharmanutra.it

118

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 761.F

View More

Performance Overview: 761.F

Trailing total returns as of 6/2/2025, which may include dividends or other distributions. Benchmark is FTSE MIB Index (FTSEMIB.MI) .

YTD Return

761.F
6.25%
FTSE MIB Index (FTSEMIB.MI)
16.96%

1-Year Return

761.F
4.62%
FTSE MIB Index (FTSEMIB.MI)
15.92%

3-Year Return

761.F
20.33%
FTSE MIB Index (FTSEMIB.MI)
63.69%

5-Year Return

761.F
34.05%
FTSE MIB Index (FTSEMIB.MI)
110.76%

Compare To: 761.F

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 761.F

View More

Valuation Measures

Annual
As of 5/30/2025
  • Market Cap

    479.06M

  • Enterprise Value

    472.36M

  • Trailing P/E

    29.04

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    3.99

  • Price/Book (mrq)

    7.39

  • Enterprise Value/Revenue

    3.95

  • Enterprise Value/EBITDA

    14.70

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.30%

  • Return on Assets (ttm)

    14.88%

  • Return on Equity (ttm)

    28.39%

  • Revenue (ttm)

    116.15M

  • Net Income Avi to Common (ttm)

    16.61M

  • Diluted EPS (ttm)

    1.71

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    29.1M

  • Total Debt/Equity (mrq)

    39.02%

  • Levered Free Cash Flow (ttm)

    12.86M

Research Analysis: 761.F

View More

Company Insights: 761.F

Research Reports: 761.F

View More